Riskpilot← Back to searchSign inGet full accessSpeciallægerne Centrum Reumatologerne ApS
APSActiveCVR 36945966Slotsarkaderne 227Medical specialists activities · NACE 8622Est. 20155 employees
Revenue 2025
DKK 3M
+3% vs 2024
EBITDA margin
25.0%
+47% vs 2024
Equity ratio
61.2%
Financial strength
Net profit 2025
DKK 563K
+65% vs 2024
| Revenue | DKK 3M | +3% |
| EBITDA | DKK 751K | +47% |
| Net profit | DKK 563K | +65% |
| Total assets | DKK 1M | +34% |
| Equity | DKK 616K | +25% |
| Employees | 5 | — |
Legal name
Speciallægerne Centrum Reumatologerne ApS
CVR number
36945966
Legal form
Anpartsselskab
NACE code
8622 · Medical specialists activities
Founded
1. juli 2015
Share capital
DKK 50.000
Employees
5 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at udøve drift af speciallægevirksomhed og virksomhed, der er naturligt forbundet hermed.
Address
Slotsarkaderne 227
Phone
+4548266823
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2.004 | 1.930 | 2.808 | 2.907 | 3.001 |
| Staff expenses | -1.619 | -1.927 | -1.698 | -2.396 | -2.251 |
| EBITDA | 384 | 3 | 1.110 | 511 | 751 |
| Depreciation & amort. | -93 | -73 | -73 | -65 | -27 |
| EBIT | 291 | -70 | 1.037 | 445 | 723 |
| Net financials | 10 | 13 | 22 | -11 | 0 |
| Profit before tax | 301 | -57 | 1.059 | 434 | 723 |
| Tax | 75 | -34 | 244 | 93 | 161 |
| Net profit | 227 | -22 | 815 | 341 | 563 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1.257 | 967 | 1.327 | 751 | 1.007 |
| Equity | 1.067 | 645 | 910 | 492 | 616 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 174 | 306 | 400 | 259 | 391 |
| Total debt | 174 | 306 | 400 | 259 | 391 |
EBITDA margin
25.0%
This company
15.8%
Market median
+58% vs market
20212025
Equity ratio
61.2%
This company
38.2%
Market median
+60% vs market
20212025
Return on equity
91.4%
This company
18.4%
Market median
+397% vs market
20212025
Net profit margin
18.7%
This company
8.1%
Market median
+131% vs market
20212025
Asset turnover
2.98×
This company
1.12×
Market median
+166% vs market
20212025
Debt / equity
0.63×
This company
0.62×
Market median
+2% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
KA Management | Management | 2015 |
AA Founder | Founder | 2015 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2020 | |
| Company | 50–66.65% | 50–66.65% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Speciallægen FZJ Holding ApS
Speciallægerne Centrum Reumatologerne ApS Board members of Speciallægerne Centrum Reumatologerne ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Khurram Ashraf | Management | 0 companies |
| Ali Ahmed Theibich | Founder | 0 companies |